Commentary|Videos|March 28, 2025
The Role of IO/Chemo Combinations in Frontline Advanced/Recurrent Endometrial Cancer
Author(s)Christian Marth, MD, PhD, John Chan, MD
Christian Marth, MD, PhD, and John Chan, MD, discuss frontline chemoimmunotherapy combinations in advanced endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
3
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5